MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today)

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

June 18, 2003

By Aaron Lorenzo

Boston Life Sciences Plans Another Altropane Phase III

June 18, 2003

By Aaron Lorenzo

Boston Life Sciences Plans Another Altropane Phase III

June 18, 2003

By Aaron Lorenzo

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

June 18, 2003

By Aaron Lorenzo

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...